It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The vertebrate main-body axis is laid down during embryonic stages in an anterior-to-posterior (head-to-tail) direction, driven and supplied by posteriorly located progenitors. Whilst posterior expansion and segmentation appears broadly uniform along the axis, there is developmental and evolutionary support for at least two discrete modules controlling processes within different axial regions: a trunk and a tail module. Here, we identify Nuclear receptor subfamily 6 group A member 1 (Nr6a1) as a master regulator of trunk development in the mouse. Specifically, Nr6a1 was found to control vertebral number and segmentation of the trunk region, autonomously from other axial regions. Moreover, Nr6a1 was essential for the timely progression of Hox signatures, and neural versus mesodermal cell fate choice, within axial progenitors. Collectively, Nr6a1 has an axially-restricted role in all major cellular and tissue-level events required for vertebral column formation, supporting the view that changes in Nr6a1 levels may underlie evolutionary changes in axial formulae.
The authors identify Nuclear receptor subfamily 6 group A member 1 (Nr6a1) as a master regulator of elongation, segmentation, patterning and lineage allocation specifically within the trunk region of the mouse, acting downstream of the major signals known to control vertebral column formation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Monash University, EMBL Australia, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Australian Regenerative Medicine Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
2 Monash University, Australian Regenerative Medicine Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Department of Anatomy and Developmental Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash Biomedicine Discovery Institute, Development and Stem Cells Program, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
3 Stowers Institute for Medical Research, Kansas City, USA (GRID:grid.250820.d) (ISNI:0000 0000 9420 1591)
4 Stowers Institute for Medical Research, Kansas City, USA (GRID:grid.250820.d) (ISNI:0000 0000 9420 1591); University of Nicosia, Nicosia, Cyprus (GRID:grid.413056.5) (ISNI:0000 0004 0383 4764)
5 Stowers Institute for Medical Research, Kansas City, USA (GRID:grid.250820.d) (ISNI:0000 0000 9420 1591); University of Kansas Medical Center, Department of Anatomy and Cell Biology, Kansas City, USA (GRID:grid.412016.0) (ISNI:0000 0001 2177 6375)